doxepin and Chronic Insomnia
doxepin has been researched along with Chronic Insomnia in 36 studies
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.
doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
" He was prescribed doxepin for insomnia and four antiepileptics for seizures." | 8.31 | Chronic Doxepin Toxicity Masquerading as Epilepsy in a 10-Year-Old Boy. ( Burns, MM; Watson, CJ; Whitledge, JD, 2023) |
" He was prescribed doxepin for insomnia and four antiepileptics for seizures." | 4.31 | Chronic Doxepin Toxicity Masquerading as Epilepsy in a 10-Year-Old Boy. ( Burns, MM; Watson, CJ; Whitledge, JD, 2023) |
"Insomnia is a distinct disorder that is common, yet underrecognized and undertreated in primary care." | 3.01 | Insomnia Management: A Review and Update. ( Shaha, DP, 2023) |
"Sleep outcomes included insomnia scales, clinical global impression, sleep diaries and actigraphy." | 2.78 | Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study. ( Bailes, S; Creti, L; Fichten, C; Libman, E; Pelletier, A; Postuma, RB; Rios Romenets, S, 2013) |
"In elderly adults with insomnia, DXP 6 mg produced significant improvements in sleep maintenance, sleep duration, and sleep quality endpoints that were sustained throughout the trial." | 2.77 | Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. ( Essink, B; Heith Durrence, H; Lankford, A; Ludington, E; Rogowski, R; Roth, T, 2012) |
"Patients meeting DSM-IV-TR criteria for primary insomnia were randomized to 35 days of nightly treatment with DXP 3 mg (n=75), DXP 6 mg (n=73), or placebo (PBO; n=73), followed by 2 nights of single-blind PBO to evaluate discontinuation (DC) effects." | 2.76 | Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. ( Durrence, HH; Jochelson, P; Krystal, AD; Lankford, A; Ludington, E; Rogowski, R; Roth, T, 2011) |
"In this model of transient insomnia, DXP 6mg demonstrated significant improvements in sleep onset, sleep maintenance, sleep duration and sleep quality, and also appeared to reduce early morning awakenings." | 2.75 | Efficacy and safety of doxepin 6 mg in a model of transient insomnia. ( Heith Durrence, H; Jochelson, P; Lankford, A; Ludington, E; Peterson, G; Rogowski, R; Roth, T; Scharf, M, 2010) |
"Subjects meeting DSM-IV-TR criteria for primary insomnia were randomized to 12 weeks of nightly treatment with doxepin (DXP) 1 mg (n = 77) or 3 mg (n = 82), or placebo (PBO; n = 81)." | 2.75 | Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. ( Durrence, HH; Jochelson, P; Krystal, AD; Ludington, E; Rogowski, R; Roth, T; Scharf, M, 2010) |
" All 3 doxepin doses had side effect profiles comparable to placebo, with no spontaneously reported anticholinergic effects, no memory impairment, and no significant next-day residual effects." | 2.73 | Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. ( Cohn, M; Ereshefsky, L; Feldman, N; Hull, S; Lankford, A; Mayleben, D; Rogowski, R; Roth, T; Scharf, M, 2008) |
"In adults with primary insomnia, doxepin 1 mg, 3 mg, and 6 mg was well-tolerated and produced improvement in objective and subjective sleep maintenance and duration endpoints that persisted into the final hour of the night." | 2.73 | Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. ( Corser, B; Hull, S; Koshorek, G; Lankford, A; Rogowski, R; Roth, T; Schwartz, H; Seiden, D, 2007) |
"Although in some patients rebound insomnia and specific side effects must be considered, our findings give a further rationale for the use of antidepressants in the treatment of primary insomnia." | 2.71 | The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. ( Cohrs, S; Hajak, G; Huether, G; Jordan, W; Rodenbeck, A; Rüther, E, 2003) |
"Long-term doxepin treatment of chronic insomniac patients not only improves sleep but also restores nocturnal melatonin secretion in these patients." | 2.68 | Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. ( Adler, L; Bandelow, B; Hajak, G; Herrendorf, G; Huether, G; Rodenbeck, A; Rüther, E; Staedt, J, 1996) |
"Understanding the risks and benefits of insomnia medications is critical." | 2.55 | Insomnia: Pharmacologic Therapy. ( Hainer, BL; Matheson, E, 2017) |
"Geriatric patients often experience insomnia because of physiological and neurological changes that occur during the aging process." | 2.55 | A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients. ( Edmonds, C; Swanoski, M, 2017) |
"Such approach to treatment of insomnia in depressed patients protects them against dependence on hypnotic drugs." | 2.47 | [The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine]. ( Wichniak, A; Wierzbicka, A, 2011) |
"Doxepin is a tricyclic compound that has been used extensively for the treatment of depressive and anxiety disorders for approximately thirty years." | 2.45 | Low-dose doxepin for the treatment of insomnia: emerging data. ( Goforth, HW, 2009) |
" Although these clinical actions are classically attributed to blockade of the H1 receptor, recent findings with H1 selective agents and H1 selective dosing of older agents are challenging these notions and suggest that some of the clinical limitations of current H1-blocking agents at their currently utilized doses could be attributable to other properties of these drugs, especially to their simultaneous actions on muscarinic, cholinergic, and adrenergic receptors." | 2.44 | Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. ( Stahl, SM, 2008) |
"Pediatric insomnia is a widespread problem and especially difficult to manage in children with neurodevelopmental disorders." | 1.56 | Doxepin in children and adolescents with symptoms of insomnia: a single-center experience. ( Kothare, SV; Pavkovic, I; Shah, YD; Stringel, V, 2020) |
" One of these compounds, 10a, showed equivalent efficacy in a rat EEG/EMG model to a previously identified clinical candidate and a potentially superior pharmacokinetic profile as determined from a human microdose study." | 1.36 | Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia. ( Beaton, G; Bradbury, MJ; Coon, T; Crowe, PD; Hernandez, LM; Hoare, SR; Huang, C; Jalali, K; Li, BF; Madan, A; Malany, S; Marinkovic, D; Moree, WJ; Petroski, RE; Sacaan, A; Tucci, FC; Wang, H; Wen, J; Yang, C; Yu, J; Zamani-Kord, S, 2010) |
"Doxepin is a tricyclic antidepressant with a subnanomolar affinity for the histamine H(1) (H(1)) receptor." | 1.35 | Selective histamine H(1) antagonism: a novel approach to insomnia using low-dose doxepin. ( Owen, RT, 2009) |
"Since insomnia was not influenced by clonidine, we offered 100 mg doxepine and/or 10 mg nitrazepam (the latter only until day 4 of treatment)." | 1.27 | [Clonidine for the treatment of heroin withdrawal syndrome]. ( Hermann, P; Presslich, O; Schanda, H, 1983) |
"Desipramine was associated with a much higher frequency of jitteriness than was imipramine." | 1.27 | The jitteriness syndrome in panic disorder patients treated with antidepressants. ( Balon, R; Lycaki, H; Pohl, R; Yeragani, VK, 1988) |
Research
Studies (36)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (13.89) | 18.7374 |
1990's | 3 (8.33) | 18.2507 |
2000's | 8 (22.22) | 29.6817 |
2010's | 15 (41.67) | 24.3611 |
2020's | 5 (13.89) | 2.80 |
Authors
Authors | Studies |
---|---|
Moree, WJ | 1 |
Li, BF | 1 |
Zamani-Kord, S | 1 |
Yu, J | 1 |
Coon, T | 1 |
Huang, C | 1 |
Marinkovic, D | 1 |
Tucci, FC | 1 |
Malany, S | 1 |
Bradbury, MJ | 1 |
Hernandez, LM | 1 |
Wen, J | 1 |
Wang, H | 1 |
Hoare, SR | 1 |
Petroski, RE | 1 |
Jalali, K | 1 |
Yang, C | 1 |
Sacaan, A | 1 |
Madan, A | 1 |
Crowe, PD | 1 |
Beaton, G | 1 |
De Crescenzo, F | 1 |
D'Alò, GL | 1 |
Ostinelli, EG | 1 |
Ciabattini, M | 1 |
Di Franco, V | 1 |
Watanabe, N | 1 |
Kurtulmus, A | 1 |
Tomlinson, A | 1 |
Mitrova, Z | 1 |
Foti, F | 1 |
Del Giovane, C | 1 |
Quested, DJ | 1 |
Cowen, PJ | 1 |
Barbui, C | 1 |
Amato, L | 1 |
Efthimiou, O | 1 |
Cipriani, A | 1 |
Shaha, DP | 1 |
Whitledge, JD | 1 |
Watson, CJ | 1 |
Burns, MM | 1 |
Shah, YD | 1 |
Stringel, V | 1 |
Pavkovic, I | 1 |
Kothare, SV | 1 |
Matheson, E | 1 |
Hainer, BL | 1 |
Um, MY | 1 |
Kim, S | 1 |
Jin, YH | 1 |
Yoon, M | 1 |
Yang, H | 1 |
Lee, J | 1 |
Jung, J | 1 |
Urade, Y | 1 |
Huang, ZL | 1 |
Kwon, S | 1 |
Cho, S | 1 |
Dupuis, G | 1 |
Vaugeois, JM | 1 |
Rios Romenets, S | 1 |
Creti, L | 1 |
Fichten, C | 1 |
Bailes, S | 1 |
Libman, E | 1 |
Pelletier, A | 1 |
Postuma, RB | 1 |
Crow, JM | 1 |
Yeung, WF | 1 |
Chung, KF | 1 |
Yung, KP | 1 |
Ng, TH | 1 |
Edmonds, C | 1 |
Swanoski, M | 1 |
Stahl, SM | 1 |
Scharf, M | 3 |
Rogowski, R | 6 |
Hull, S | 2 |
Cohn, M | 1 |
Mayleben, D | 1 |
Feldman, N | 1 |
Ereshefsky, L | 1 |
Lankford, A | 5 |
Roth, T | 6 |
Goforth, HW | 1 |
Owen, RT | 1 |
Weber, J | 1 |
Siddiqui, MA | 1 |
Wagstaff, AJ | 1 |
McCormack, PL | 1 |
Heith Durrence, H | 2 |
Jochelson, P | 3 |
Peterson, G | 1 |
Ludington, E | 4 |
Krystal, AD | 2 |
Durrence, HH | 2 |
Wichniak, A | 1 |
Wierzbicka, A | 1 |
Clark, MS | 1 |
Smith, PO | 1 |
Jamieson, B | 1 |
Essink, B | 1 |
Rodenbeck, A | 5 |
Cohrs, S | 2 |
Jordan, W | 1 |
Huether, G | 4 |
Rüther, E | 4 |
Hajak, G | 5 |
Singh, H | 1 |
Becker, PM | 1 |
Schwartz, H | 1 |
Koshorek, G | 1 |
Corser, B | 1 |
Seiden, D | 1 |
Schanda, H | 1 |
Presslich, O | 1 |
Hermann, P | 1 |
Adler, L | 1 |
Bandelow, B | 1 |
Herrendorf, G | 1 |
Staedt, J | 1 |
Voderholzer, U | 1 |
Riemann, D | 1 |
Hohagen, F | 1 |
Berger, M | 1 |
Elwan, O | 1 |
Taher, Y | 1 |
Allam, M | 1 |
Hassan, MA | 1 |
Smith, JA | 1 |
Renshaw, DC | 1 |
Pohl, R | 1 |
Yeragani, VK | 1 |
Balon, R | 1 |
Lycaki, H | 1 |
Lee, HK | 1 |
Reviews
12 reviews available for doxepin and Chronic Insomnia
Article | Year |
---|---|
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
Topics: Adult; Benzodiazepines; Doxepin; Eszopiclone; Humans; Melatonin; Network Meta-Analysis; Randomized C | 2022 |
Insomnia Management: A Review and Update.
Topics: Doxepin; Humans; Sleep; Sleep Initiation and Maintenance Disorders; Zolpidem | 2023 |
Insomnia: Pharmacologic Therapy.
Topics: Benzodiazepines; Doxepin; Humans; Hypnotics and Sedatives; Melatonin; Sleep Initiation and Maintenan | 2017 |
Doxepin for insomnia: a systematic review of randomized placebo-controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Doxepin; Drug Therapy, | 2015 |
A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
Topics: Aged; Aged, 80 and over; Azepines; Benzofurans; Cyclopropanes; Doxepin; Humans; Hypnotics and Sedati | 2017 |
Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines.
Topics: Doxepin; Histamine Antagonists; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Hu | 2008 |
Low-dose doxepin for the treatment of insomnia: emerging data.
Topics: Antidepressive Agents, Tricyclic; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Doxep | 2009 |
Low-dose doxepin: in the treatment of insomnia.
Topics: Adult; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Doxepin; Female; Humans; Male; Sl | 2010 |
Low-dose doxepin (Silenor) for insomnia.
Topics: Antidepressive Agents, Tricyclic; Chemistry, Pharmaceutical; Disorders of Excessive Somnolence; Doxe | 2010 |
[The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine].
Topics: Amitriptyline; Antidepressive Agents; Depression; Doxepin; Humans; Mianserin; Mirtazapine; Sleep; Sl | 2011 |
Novel therapeutic usage of low-dose doxepin hydrochloride.
Topics: Animals; Dose-Response Relationship, Drug; Doxepin; Drug Administration Schedule; Humans; Sleep Init | 2007 |
Nocturnal melatonin secretion and its modification by treatment in patients with sleep disorders.
Topics: Adult; Circadian Rhythm; Doxepin; Flunitrazepam; Humans; Hypnotics and Sedatives; Melatonin; Middle | 1999 |
Trials
12 trials available for doxepin and Chronic Insomnia
Article | Year |
---|---|
Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study.
Topics: Actigraphy; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Cognitive Behavioral T | 2013 |
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.
Topics: Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Doxepin; Drug-Relat | 2008 |
Efficacy and safety of doxepin 6 mg in a model of transient insomnia.
Topics: Adult; Double-Blind Method; Doxepin; Humans; Hypnotics and Sedatives; Polysomnography; Sleep; Sleep | 2010 |
Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.
Topics: Aged; Antidepressive Agents, Tricyclic; Chronic Disease; Dose-Response Relationship, Drug; Double-Bl | 2010 |
Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.
Topics: Adolescent; Adult; Chronic Disease; Double-Blind Method; Doxepin; Female; Humans; Hypnotics and Seda | 2011 |
Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.
Topics: Aged; Aged, 80 and over; Chronic Disease; Doxepin; Female; Histamine H1 Antagonists; Humans; Male; M | 2012 |
The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks.
Topics: Adult; Antidepressive Agents, Tricyclic; Cross-Over Studies; Double-Blind Method; Doxepin; Female; H | 2003 |
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Chronic Disease; Cross-Over Studies; Double-Bli | 2007 |
Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia.
Topics: Adult; Antidepressive Agents, Tricyclic; Area Under Curve; Arousal; Cross-Over Studies; Double-Blind | 1996 |
Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study.
Topics: Antidepressive Agents, Tricyclic; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Me | 2001 |
A comparative study of antidepressants in the treatment of depressive states.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Depression; Dibenzazepines; Dibenzocycloheptenes; | 1976 |
A clinical study of insomnia.
Topics: Adult; Aged; Anxiety Disorders; Clinical Trials as Topic; Depression; Doxepin; Drug Therapy, Combina | 1975 |
Other Studies
12 other studies available for doxepin and Chronic Insomnia
Article | Year |
---|---|
Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.
Topics: Animals; Cytochrome P-450 CYP2D6; Dimethindene; Electroencephalography; Histamine H1 Antagonists; Hu | 2010 |
Chronic Doxepin Toxicity Masquerading as Epilepsy in a 10-Year-Old Boy.
Topics: Ataxia; Child; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Doxepin; Epilepsy; Humans; Male; S | 2023 |
Doxepin in children and adolescents with symptoms of insomnia: a single-center experience.
Topics: Adolescent; Child; Doxepin; Humans; Melatonin; Retrospective Studies; Sleep; Sleep Initiation and Ma | 2020 |
A novel neurological function of rice bran: a standardized rice bran supplement promotes non-rapid eye movement sleep in mice through histamine H
Topics: Action Potentials; Animals; Dietary Fiber; Dietary Supplements; Doxepin; Electroencephalography; His | 2017 |
[The interesting anti-H1 effects in maintenance insomnia: A reflection on the comparative advantages of doxylamine and doxepin].
Topics: Doxepin; Doxylamine; Histamine H1 Antagonists; Humans; Hypnotics and Sedatives; Patient Education as | 2020 |
Insomnia: chasing the dream.
Topics: Animals; Arousal; Azabicyclo Compounds; Azepines; Benzodiazepines; Cognitive Behavioral Therapy; Dox | 2013 |
Selective histamine H(1) antagonism: a novel approach to insomnia using low-dose doxepin.
Topics: Adult; Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response | 2009 |
FPIN's clinical inquiries: Antidepressants for the treatment of insomnia in patients with depression.
Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Dose-Response Re | 2011 |
[Clonidine for the treatment of heroin withdrawal syndrome].
Topics: 2-Hydroxyphenethylamine; Clonidine; Dose-Response Relationship, Drug; Doxepin; Drug Administration S | 1983 |
Melatonin in insomniac patients and effects of sleep medication.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Double-Blind Method; Doxepin; Flunitra | 1996 |
The jitteriness syndrome in panic disorder patients treated with antidepressants.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Diso | 1988 |
Dystonic reactions to amitriptyline and doxepin.
Topics: Adult; Amitriptyline; Basal Ganglia Diseases; Depressive Disorder; Doxepin; Dystonia; Female; Humans | 1988 |